Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 24 of 24 publications.

von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.

Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.

Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).

Bartosch WJ, Bray JW, Davis KL, Graver L, Schroeder D, Miller K. Variations in mental health and substance abuse service provider types between medicaid and state agencies in three states. Presented at the 132nd Annual Meeting of the American Public Health Association; November 2004.

Vickers AD, Mellor P, Brice R. Over-estimation in market simulations: an explanation and solution to the problem with particular reference to the pharmaceutical industry. Presented at the Eleventh Sawtooth Software Conference; October 6, 2004. San Diego, CA.

Brogan AJ, Mauskopf JA, Quattek K, Jordan J. Lower resource use of 908/ritonavir compared to nelfinavir may be explained by better tolerability. Poster presented at the 42nd Annual Meeting of the Infectious Disease Society of America; October 2004.

Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004 May 4;140(9):689-99.

Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.

Bell TJ, Tang SS, Candrilli SD, Jamieson MJ. Evaluation of hypertension prevalence and blood pressure goal attainment using data from the 1999-2000 national health and nutrition examination survey (NHANES 1999-2000). Poster presented at the 19th Annual Scientific Meeting and Exposition of the American Society of Hypertension; May 2004.

Battleman DS, Candrilli SD, Burhani S, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among us adults in 2000, utilizing data from the national health and nutrition examination survey (NHANES III). Poster presented at the 16th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; March 2004.

Hicks KA. Operations research in action. Presented at the Expanding Your Horizons in Math, Science and Technology; March 2004. Research Triangle Park, NC.

Finkelstein EA, Hicks KA. Obesity cost calculator for employers. Presented at the 2004 National Business Group on Health Founding Board Meeting; February 2004.

West R, Curry SJ, Fiore MC, Sullivan SD, Neighbors D, Gilsenan AW, Smadja E, Lavaud V. Attempt cohort: weight gain concern of smokers intending to quit. Poster presented at the 10th Annual Scientific Sessions of the Society for Research on Nicotine and Tobacco; February 2004. Scottsdale, AZ.

Curry SJ, Fiore MC, West R, Sullivan SD, Nonnemaker J, Neighbors D, Zhou X, Jourdan S, Brouard R. Preliminary data from assessment toward tobacco economical and medical prospective trial (ATTEMPT)—A global longitudinal cohort study of the natural history of quit attempts. Poster presented at the 10th Annual Scientific Sessions of the Society for Research on Nicotine and Tobacco; February 2004. Scottsdale, AZ.

Mauskopf JA, Shih T, Baker T, Borker R, Stanford RH, Jhingran P. Budget impact analysis: combination fluticasone and salmeterol for asthma. Value Health. 2004 Jan 1;7(3):312.

Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.

Nicholls TJ, Carpenter BG, Rogers DJ, Cook DJ, Wolowacz SE, Smart JD. An investigationn of lectin binding sites on unfixed corneal and conjunctival surfaces of rats. Poster presented at the Proceedings of IinterLec; 2004.

Mauskopf J, Candrilli S, Segal R, Schaber C, Tsai H. The current burden of respiratory distress syndrome (RDS) in very low birth-weight(VLBW) infants. Pediatr Res. 2004 Jan 1;55(4):549A.

Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.

Abeysinghe SS, Stenson PD PD, Krawczak M, Cooper DN DN. Gross Rearrangement Breakpoint Database (GRABDTM). Hum Mutat. 2004;23(3):219-21.

Vickers AD. Adapting market simulations from choice-based conjoint analysis to pharmaceutical scenarios. Presented at the Annual Sawtooth Software Conference; 2004.

Hill AR, Aspinall P, Armbrecht A, Lumsden C, Nelson P, Brice R, Vickers AD. Utilities for quality of life from time trade-off and conjoint analysis in age-related macular degeneration. Poster presented at the Heriott Watt University; 2004.

Bacolla A, Jaworski A, Larson JE, Jakupciak JP, Chuzhanova N, Abeysinghe SS, O'Connell CD, Cooper DN, Wells RD. Breakpoints of gross deletions coincide with non-B DNA conformations. Proc Natl Acad Sci U S A. 2004;101(39):14162-7.

Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.